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, Oral Glucose Tolerance Test in Liver Recipients Treated With FK 506 
L. Mieles, S. Todo, J.J. Fung, A. Jain, H. Furukawa, M. Susuki, and T.E. Starzl 
I NITIAL human trials with FK 506 conducted at the University of Pittsburgh have demonstrated a remark-
able immunosuppressive effect of the drug on liver. kid-
ney, and pancreatic transplants. 1-3 It is expected that the 
drug may be used more extensively in the field of trans-
plantation over the next few years. Since some of the early 
experiments suggested that FK 506 might be diabeto-
genic.4 oral glucose tolerance tests were performed in 12 
liver transplant recipients who received FK 506, searching 
for possible derangements in glucose metabolism. 
MATERIALS AND METHODS 
The 12 patients whose immunosuppression consisted of FK 506 
and low doses of prednisone were all adult individuals with no 
acute illness. no previous history of diabetes mellitus, and normal 
fasting blood sugar levels before transplantation. Table I shows 
the age, sex, steroid dose, and time after transplant of these 12 
patients. 
The test was conducted in the following fashion: after a 100hour 
fast, a sample was obtained, and 75 g of glucose was administered 
orally. Samples for venous serum sugar levels were obtained at 30 
minutes and I, 2, 3, 4, and 5 hours. Simultaneous insulin levels 
were done at fasting and at hourly intervals for 5 hours. The 
glucose determinations were made using the Kodak Ektachem 
Colorimetric method (Eastman Kodak Company, Rochester, 
NY), while the insulin measurements were done by the radioim-
munoassay method (1251 Insulin Radioimmunoassay Kit, Cam-
bridge Medical Diagnostics). The results of this test are shown in 
Figs I and 2. 
RESULTS 
None of the patients were on insulin therapy. The fasting 
blood sugar levels were normal in II patients and abnormal 
in one (patient no. 4). Their mean values were 99 ± 18 (SD) 
mg/dl (Table I). In six patients, the oral glucose tolerance 
test was considered normal (patients no. 2. 3, 6, 9, to. and 
12). In two patients (nos. 4 and 5). the results were 
consistent with incipient diabetes mellitus. while in the 
remaining four patients (nos. I, 7, 8, and II). although not 
entirely normal (a 2-hour sample <200 and> 140 mg/dl 
with intermediate values of <200 mg/dl), the tests could 
not be classified as being indicative of diabetes or of 
impaired glucose tolerance tests. The fasting insulin levels 
were <20 Io'U/ml in all patients, with mean peak insulin 
levels of 42 ± 28 ~r/ml (Table I). The insulin curves are 
shown in Fig 2, and most follow a normal pattern. Again. 
patient no. 4 presented with the lowest peak insulin levels 
and a flat insulin curve. This patient had a family history of 
diabetes mellitus and a DR4 on human leukocyte antigen 
typing, which suggested that heredity was a major contrib-
utor to this patient's abnormal glucose tolerance test. 
Although asymptomatic, the patient has continued to have 
mildly elevated fasting blood sugar levels. The other 
patient with a diabetic-type curve (patient no. 5) has 
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Table 1. Features of the 12 Liver Transplant Recipients Tested 
Prednisone Fasting Blood Peak Insulin 
Patient Age Days After Dose Sugar Level Level 
No. (yr) Sex Transplant (mgld) (mgldl) /LU1ml) 
41 F 25 5 82 30 
2 31 M 15 10 95 42 
3 18 M 25 5 100 66 
4 38 M 19 10 154 22 
5 42 M 23 0 99 41 
6 39 M 34 5 90 23 
7 49 M 24 0 85 35 
8 28 M 21 20 115 26 
9 55 M 35 10 103 37 
10 36 F 24 10 99 128 
11 33 F 27 5 97 34 
12 36 M 49 5 80 27 
Mean :t SD 37 ± 9 27 :t 9 7±5 99 ± 18 48 ± 28 
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remained asymptomatic, with nonnal fasting blood sugar 
levels. This last patient has been completely weaned from 
steroids. DR typing for this patient was not available. 
DISCUSSION 
Posttransplant hyperglycemia is a well-recognized hazard 
of organ transplantation. The reason may be multifactorial. 
although drug toxicity may playa major role, since most 
standard immunosuppressive regimens contain prednisone 
and/or CyA, which are known to be diabetogenic in 
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Fig 1. Oral glucose toler-
I ance test in 12 liver trans-
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506. 
humans. 5-8 Since similar effects had been ascribed to FK 
506 in experimental animals.4 we were prompted to per-
fonn the present study. A significant diabetogenic effect of 
FK 506 on liver transplant recipients, at least during the 
first weeks following transplantation, was not found to be 
different than in patients under conventional immunosup-
pression. Longer-tenn studies are needed to detennine 
whether the minimal abnormalities seen in some of these 
patients will eventually disappear or whether they will 
evolve into a diabetic state. 
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Fig 2. Corresponding insulin 
curve in the 12 liver transplant 
recipients receiving FK 506. 
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